Form 13-F position report

* DEXCOM INC

Reported by PIER 88 INVESTMENT PARTNERS LLC

DXCM CUSIP 252131107 Manager CIK 0001697366

Reported 13,630 shares, up 3,920 (40.4%) from the prior quarter.

Reported value 14.7%; share count 40.4% vs. the prior quarter.

Added
% of reported 13F value 0.35% This manager · Q2 2024
Shares 13,630 Quarter-end amount reported
Reported value $1,545,369 Fair value at quarter end
Consecutive quarters held 19 Through Q2 2024

Reported position value by quarter

Reported position value by quarter

Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.

Reported position value by quarter
Date Holding Value
2021-12-31 2661000
2022-03-31 3456000
2022-06-30 607000
2022-09-30 1705000
2022-12-31 1853739
2023-03-31 2459531
2023-06-30 2400567
2023-09-30 1191441
2023-12-31 971625
2024-03-31 1346777
2024-06-30 1545369
2024-09-30 429056
2024-12-31 497728
2025-03-31 222625
2025-06-30 545563
2025-09-30 0

Quarterly position history

How this manager's reported quarter-end position changed over time.

16 quarters
Quarterly reported position history for * DEXCOM INC held by PIER 88 INVESTMENT PARTNERS LLC.
Quarter Activity Shares Change % of reported 13F Reported value Filed Source filing
Q3 2025 Reduced 0 -6,250 (-100.0%) 0 $0 2025-10-31
Q2 2025 Added 6,250 +2,990 (91.7%) 0.1% $545,563 2025-08-07
Q1 2025 Reduced 3,260 -3,140 (-49.1%) 0.04% $222,625 2025-05-06
Q4 2024 Unchanged 6,400 0 (0.0%) 0.1% $497,728 2025-02-12
Q3 2024 Reduced 6,400 -7,230 (-53.0%) 0.09% $429,056 2024-11-06
Q2 2024 Added 13,630 +3,920 (40.4%) 0.35% $1,545,369 2024-08-06
Q1 2024 Added 9,710 +1,880 (24.0%) 0.33% $1,346,777 2024-05-10
Q4 2023 Reduced 7,830 -4,940 (-38.7%) 0.24% $971,625 2024-02-12
Q3 2023 Reduced 12,770 -5,910 (-31.6%) 0.3% $1,191,441 2023-11-09
Q2 2023 Reduced 18,680 -2,490 (-11.8%) 0.59% $2,400,567 2023-08-07
Q1 2023 Added 21,170 +4,800 (29.3%) 0.6% $2,459,531 2023-05-09
Q4 2022 Reduced 16,370 -4,810 (-22.7%) 0.45% $1,853,739 2023-02-08
Q3 2022 Added 21,180 +13,040 (160.2%) 0.41% $1,705,000 2022-11-14
Q2 2022 Reduced 8,140* -18,884 (-69.9%) 0.14% $607,000 2022-08-12
Q1 2022 Added 6,756 +1,800 (36.3%) 1.24% $3,456,000 2022-05-13
Q4 2021 Reduced 4,956 -600 (-10.8%) 0.57% $2,661,000 2022-02-14
Five years are shown. A free account unlocks the complete reported history. Unlock full history

Who else reported the position

1137 managers reported * DEXCOM INC for Q2 2024.

Managers reporting * DEXCOM INC in Q2 2024.
Manager Activity Shares Change % of reported 13F Reported value Tenure
VANGUARD GROUP INC Added 46,513,184 +1,909,439 0.1% $5,273,664,803 45 qtrs
BlackRock Inc Added 34,519,365 +596,713 0.09% $3,913,805,646 45 qtrs
STATE STREET CORPORATION Added 16,308,682 +93,864 0.08% $1,849,078,365 45 qtrs
BAILLIE GIFFORD & CO Reduced 15,325,931 -362,465 1.35% $1,737,654,056 45 qtrs
Capital Research Global Investors Reduced 11,945,527 -1,490,365 0.3% $1,354,395,929 14 qtrs
SANDS CAPITAL MANAGEMENT LLC Reduced 10,606,503 -290,261 3.53% $1,202,565,310 18 qtrs
FMR LLC Added 9,792,171 +445,223 0.07% $1,110,236,286 45 qtrs
GEODE CAPITAL MANAGEMENT LLC Added 9,723,468 +545,273 0.1% $1,099,655,464 45 qtrs
Capital World Investors Added 8,310,007 +237,877 0.15% $942,188,611 27 qtrs
JPMorgan Chase & Co Added 6,710,983 +1,014,387 0.06% $760,891,310 45 qtrs
Premium adds each manager's conviction percentile across reporting peers.
Filing details and methodology As reported
Report period
June 30, 2024
Filed
August 06, 2024
Filing type
13F-HR
Position type
Common stock

Voting authority reported

Sole
12,530
Shared
1,100
None
0

“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.

Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.